We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Increasing Enoxaparin Dosing from 30 mg to 40 mg Does Not Affect Bleeding or VTE Risk in Bariatric Surgery Patients.
- Authors
Taylor, Ryan; Madion, Matthew; Kleppe, Kyle; Mancini, Matthew; Mancini, Gregory; Hutson, Mitchell; Yates, John; Daigle, Haley
- Abstract
This article discusses a study that aimed to investigate the effect of increasing the dosage of enoxaparin, a medication used for venous thromboembolism (VTE) prophylaxis, on the rates of VTE and bleeding events in bariatric surgery patients. The study included 990 patients who underwent bariatric surgery and received either the standard dose of 30 mg enoxaparin twice daily (control group) or an increased dose of 40 mg enoxaparin twice daily (treatment group). The results showed that increasing the enoxaparin dosage did not lead to an increased risk of bleeding events, and although there was no significant difference in VTE rates between the two groups, the higher dosage may be considered a safe option for VTE prophylaxis in this patient population. However, it is important to note that this study has limitations, such as being a single-institution retrospective review and having a predominantly female and Caucasian study population. Further research is needed to determine the optimal dosage and duration for VTE prophylaxis in bariatric surgery patients.
- Subjects
GASTRIC banding; GASTRIC bypass; BARIATRIC surgery; ENOXAPARIN; LOW-molecular-weight heparin; HEMORRHAGE
- Publication
American Surgeon, 2024, Vol 90, Issue 6, p1784
- ISSN
0003-1348
- Publication type
Article
- DOI
10.1177/00031348241241696